Hikal P/E Ratio
Hikal (HIKAL) P/E ratio is not applicable — EPS (TTM) ₹-3.96. See Healthcare peers with valid P/E ratios below.
P/E Ratio Status
N/A
Loss Making
Company is currently reporting losses
P/E Ratio Not Applicable
Company reported a loss in the most recent quarter. P/E ratio is not meaningful for loss-making periods.
Current EPS: ₹-3.96
Recent Quarterly Performance
| Quarter | EPS (₹) | Net Profit (₹ Cr) | Status |
|---|---|---|---|
| Mar 2026 | 1.17 | 14 | Profit |
| Jun 2026 | -0.60 | -7 | Loss |
| Sept 2025 | -2.83 | -35 | Loss |
| Mar 2025 | 4.07 | 50 | Profit |
| Jun 2025 | -1.82 | -22 | Loss |
| Dec 2025 | -0.48 | -6 | Loss |
| Sept 2024 | 1.48 | 18 | Profit |
| Mar 2024 | 2.76 | 34 | Profit |
Healthcare Peers with Valid P/E Ratios — HIKAL Comparison
Healthcare sector average P/E 56.79, median 32.06 — HIKAL excluded (negative EPS).
Sector Average PE
56.79
Sector Median PE
32.06
Lowest PE
1.99
Profitable Companies
200
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sunrest Lifescience | SUNREST | 1.99 | ₹66 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Colinz Laboratories | COLINZ | 3.27 | ₹9 | Low |
| Phaarmasia | PHRMASI | 3.41 | ₹59 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.03 | ₹6,361 | Low |
| Dipna Pharmachem | DPL | 4.65 | ₹12 | Low |
| JFL Life Sciences | JFLLIFE | 4.95 | ₹67 | Low |
| Shelter Pharma | SHELTER | 5.71 | ₹56 | Low |
| GKB Ophthalmics | GKB | 5.9 | ₹33 | Low |
| Kabra Drugs | KABRADG | 6.29 | ₹49 | Low |
Related Analysis
- For live price, revenue and the complete fundamental profile, see Hikal share price screener.
- Also explore Hikal stock price data download to track price trends across different timeframes.